Ann-Kathrin Eisfeld, MD

Articles by Ann-Kathrin Eisfeld, MD

Dr Eisfeld on Timing of Molecular Testing and the Start of Treatment in AML

May 24th 2023

Ann-Kathrin Eisfeld, MD, discusses factors to consider when deciding whether to start treatment right away or wait for molecular testing results in patients with acute myeloid leukemia.

Dr Eisfeld on Updated Guidelines for the Classification of AML

ByAnn-Kathrin Eisfeld, MD

April 18th 2023

Ann-Kathrin Eisfeld, MD, discusses recent changes to the classification of acute myeloid leukemia, and potential challenges accompanying these new guidelines.

Latest Updated Articles

Dr Eisfeld on Updated Guidelines for the Classification of AML
April 18th 2023

Ann-Kathrin Eisfeld, MD

Articles by Ann-Kathrin Eisfeld, MD

Dr Eisfeld on Timing of Molecular Testing and the Start of Treatment in AML

Dr Eisfeld on Updated Guidelines for the Classification of AML

Latest Updated Articles

Trending on OncLive

FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC

Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma

Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC

FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer

Introduction and Frontline Treatment Options for EGFR-Mutated NSCLC